Productized life sciences advisory for pharma medical affairs, medtech regulatory, and CME providers. Manuscript clinical review, KOL identification, advisory board planning, congress abstract review, and CME content development. The editorial and strategic layer between science and the clinical audience.
Or book a free 20-minute scoping call →Hospitals do not adopt because the evidence is good. They adopt because clinicians trust the case, workflows accommodate the change, and the economics survive contact with the PT committee. A3HCS works in that translation layer.
A³HCS works in the translation layer from clearance to adoption.
Clinical and regulatory pathway alignment, label-to-adoption mapping, evidence package framing for provider audiences.
How your evidence reads to a PT committee. Where it stalls. What the committee actually needs to see and from whom.
KOL identification, engagement architecture, speaker programs designed by a physician executive who has been on both sides of the podium.
Where your product lives in the clinical workflow. Who has to change behavior. Where the friction is and how to reduce it before launch.
Underserved territory. Many launches stop at the acute hospital. We extend the pathway through SNF, IRF, home health, and caregiver activation.
Three signals from current industry activity. Each one shapes how pharma and biotech navigate clinical strategy and market access.
Longtime biotech executive Jeremy Levin argues the industry is producing scientific results that once seemed impossible, but that American leadership in translating those results to patients is at risk. The gap is strategic, not scientific.
The finalized rule overhauling the No Surprises Act arbitration process compresses the cost of disputing claims. Providers are already racking up wins. For pharma and medical affairs teams, this signals sustained pressure on how drugs and devices get reimbursed through the dispute layer.
Highmark's insurance arm swung back to profitability in Q1. A financially recovered payer has more leverage in formulary positioning and prior authorization decisions. Life sciences companies in active P&T negotiations should read this as a tightening environment.
Chief Medical Officers, Medical Science Liaisons
Pre-submission manuscript review, publication strategy, and KOL briefing. The physician reviewer who reads the manuscript as the target clinical audience will read it.
Regulatory Affairs, Medical Education teams
CME alignment, congress abstracts, regulatory positioning. The editorial and strategic layer between science and the clinical audience.
One manuscript clinical review plus written feedback and a 60-minute editorial debrief.
4 to 6 weeks. Manuscript review, KOL identification, advisory board planning, written publication strategy memo.
3-month minimum. Monthly manuscript and abstract review on demand. Ongoing KOL recommendations and CME content review.
Reads manuscripts before submission, provides clinical-accuracy review, helps identify and brief KOLs for advisory boards or congress podiums, contributes to publication strategy, reviews congress abstracts, and serves as clinical voice in CME content development. Distinct from clinical research operations and regulatory affairs. Sits between science and the clinical audience.
Medical writers produce manuscripts. Agencies coordinate publications strategy. A3HCS sits one layer up. The physician reviewer who reads the manuscript as the target clinical audience will, sharpens overreaching claims, identifies credible KOLs, and signs off on accuracy before submission. We work alongside writers and agencies, not instead of them.
Tier 01: Single Publication Review at $5,000. Tier 02: Medical Affairs Package at $20,000 over four to six weeks. Tier 03: Ongoing Medical Affairs Retainer at $8,000 per month with a three-month minimum. All flat fees published. No bait pricing.
Medical affairs advisory is the editorial and strategic layer between your science and the clinical audience. You need it when a manuscript is ready for submission but has not been reviewed by the physician who will read it in practice, when you are identifying KOLs for an advisory board or congress podium, when CME content needs clinical-accuracy review, or when a P&T committee needs your drug or device positioned correctly.
Pharmaceutical companies preparing manuscripts for high-impact journals, medtech companies building KOL programs ahead of a product launch, digital health companies developing CME or continuing education content, and biotech medical affairs teams managing congress abstract strategy. Company stage ranges from late clinical-stage to commercial.
KOL identification starts with the target clinical audience and works backward — who publishes in this therapeutic area, who presents at the relevant congress, who sits on the relevant guideline committee. A3HCS maps that landscape, identifies credible candidates, and produces a KOL briefing document your medical affairs team can use for outreach and advisory board design.
Yes. Every engagement begins with a mutual NDA before any manuscript, data, or proprietary strategy is shared. References from prior engagements are available under NDA for qualified prospects after an initial scoping call.
Most useful at three points: late Phase 2 or Phase 3 when publication strategy and KOL engagement need to be in motion before data readout, at launch when medical affairs is standing up the advisory board and congress presence, and in the post-launch commercial phase when ongoing CME and publication support is needed to maintain clinical credibility.
A two-to-four-week structured diagnostic delivered as an executive memo, not a deck. It defines where your system is losing time, margin, and trust, and identifies the two-to-three corrections worth investing in next.